Expertise in
1
conditions

David Borg

Lund, M, SE 
Expertise in
1
conditions
Lund, M, SE 
OverviewLocationsClinical Research

Overview

David Borg practices in Lund, Sweden. Mr. Borg is highly rated in 1 condition, according to our data. His top areas of expertise are Esophageal Cancer, Stomach Cancer, Pancreatic Cancer, Esophagitis, and Gastrectomy.

His clinical research consists of co-authoring 24 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Lund, M, Sweden
Other Locations
Inga Maria Nilsson's Street 53, Malmoe, M 21428, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.
Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2024
Intervention Type: Drug
Study Drugs: Fluorouracil, Oxaliplatin, Irinotecan
Study Phase: Phase 2
Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.
Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.
Enrollment Status: Completed
Publish Date: February 28, 2020
Intervention Type: Radiation, Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

24 Total Publications

Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial.
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 05, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Borg's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile